Evidence map›Paper›PMID 41721154›Full record

ArticleInternational journal of clinical oncology2026

The efficacy and safety of docetaxel with cisplatin compared with other chemotherapies in definitive chemoradiotherapy for head and neck squamous cell carcinoma: a real-world study.

Takumi Kumai, Yuto Izumiya, Misaki Hayashi, Kaoru Miyakoshi, Takahiro Inoue, Hisataka Ominato, Motozumi Nakamura, Risa Wakisaka, Daisuke Araki, Michihisa Kono and 7 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takumi KumaiDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan. t-kumai@asahikawa-med.ac.jp.ORCID http://orcid.org/0000-0002-3411-671X
Yuto IzumiyaDepartment of Otolaryngology, Nikko Memorial Hospital, Muroran, Japan.
Misaki HayashiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Japan.
Kaoru MiyakoshiDepartment of Otolaryngology, Head and Neck Surgery, Kitami Red Cross Hospital, Kitami, Japan.
Takahiro InoueDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
Hisataka OminatoDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Kosei Hospital, Asahikawa, Japan.
Motozumi NakamuraDepartment of Otolaryngology, Nikko Memorial Hospital, Muroran, Japan.
Risa WakisakaDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
Daisuke ArakiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Japan.
Michihisa KonoDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
Hidekiyo YamakiDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
Kenzo OharaDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
Yoshiya IshidaDepartment of Otolaryngology, Head and Neck Surgery, Kitami Red Cross Hospital, Kitami, Japan.
Tomoki YoshizakiDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Kosei Hospital, Asahikawa, Japan.
Tetsuji WadaDepartment of Otolaryngology, Head and Neck Surgery, Kitami Red Cross Hospital, Kitami, Japan.
Nobuyuki BandohDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Japan.
Miki TakaharaDepartment of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegarding concurrent chemoradiotherapy (CCRT), the combination of docetaxel and cisplatin (DP regimen) is a promising option for treating head and neck squamous cell carcinoma (HNSCC) with a relatively low dose of cisplatin; however, its non-inferiority to other chemotherapies in efficacy and tolerability remains unclear.

methodsIn this retrospective multi-institutional study, the efficacy and safety of the DP regimen were compared with those of other chemotherapy regimens in patients who underwent CCRT for HNSCC. Overall survival, progression-free survival, and adverse effects-including estimated glomerular filtration rate (eGFR)-were evaluated as outcome measures.

resultsStudy results showed that a total of 211 patients were included. The prevalence of oropharyngeal, hypopharyngeal, and laryngeal cancer was 44%, 33%, and 17%, respectively. Overall response and recurrence rates were comparable between the DP regimen and high-dose CDDP alone. Although overall and progression-free survival tended to be longer with the DP regimen than with high-dose CDDP, the differences were not statistically significant. Neutropenia was more frequently observed with the DP regimen, but the chemotherapy completion rate was comparable to that of high-dose CDDP alone. Regarding renal function, eGFR significantly decreased with high-dose CDDP but not with the DP regimen.

conclusionsA combination of docetaxel and cisplatin in concurrent chemoradiotherapy was a favorable option for treating HNSCC with acceptable efficacy and manageable toxicity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinDocetaxelHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesCisplatinDocetaxelCCRTCisplatinDocetaxelHead and neckHNSCC

Identifiers

PMID41721154
PMCPMC13018028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.